committee meeting, FDA may conduct a lottery to determine the speakers who will be invited to participate in-person. The contact person will notify interested persons regarding their request to speak by October 30, 2026. Persons attending FDA's advisory committee meetings are advised that FDA is not responsible for providing access to electrical outlets.

For press inquiries, please contact the HHS Press Room at *https://www.hhs.gov/press-room/index.html* or 202–690–6343.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Evella Washington *CDRH_MDAC@fda.hhs.gov* (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at *https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm* for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*). This meeting notice also serves as notice that, pursuant to 21 CFR 10.19, the requirements in 21 CFR 14.22(b), (f), and (g) relating to the location of advisory committee meetings are hereby waived to allow for this meeting to take place using an online meeting platform in conjunction with the physical meeting room (see **ADDRESSES**). This waiver is in the interest of allowing greater transparency and opportunities for public participation, in addition to convenience for advisory committee members, speakers, and guest speakers. The conditions for issuance of a waiver under 21 CFR 10.19 are met.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–18920 Filed 9–15–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Document Identifier: OS–0990–0473]

Agency Information Collection Request; 30-Day Public Comment Request

AGENCY: Office for Human Research Protections (OHRP), Office of the Assistant Secretary for Health (OASH), Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. OMB will accept further comments from the public during the review and approval period.

DATES: Comments on the ICR must be received on or before October 16, 2026.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice via *www.reginfo.gov/public/do/PRAMain.* Find this information collection by selecting ''Currently under Review'' and ''Select Agency: Department of Health and Human Services''.

FOR FURTHER INFORMATION CONTACT: Natalie Klein, *Natalie.Klein@hhs.gov* or (240) 453–6900. If requesting information, please include the document identifier 0990–0473–30D and project title, ''Department of Health and Human Services (HHS) Subpart C Certification Form'' for reference.

SUPPLEMENTARY INFORMATION: Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Title of the Collection: Department of Health and Human Services (HHS) Subpart C Certification Form.

Type of Collection: Renewal.

OMB No.: 0990–0473.

Abstract: The Office for Human Research Protections (OHRP) is requesting a three-year extension of OMB No. 0990–0473, the HHS Subpart C Certification Form. The purpose of this form is to provide a simplified, standardized procedure for institutions to submit subpart C research certifications to OHRP in order to obtain authorization to include prisoners in HHS-conducted or supported human subjects research. The form also simplifies the internal process used by OHRP to review and record such certifications, resulting in faster processing while reducing unnecessary and burdensome staff time.

Likely Respondents: Institutions or Organizations operating Institutional Review Boards (IRBs) that have enrolled or are planning to enroll prisoners in human subjects research conducted or supported by HHS.

ESTIMATED ANNUALIZED BURDEN HOUR TABLE

Form name	Respondents	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total burden hours
Subpart C Certification Form	Institutions or Organizations operating Institutional Review Boards (IRBs).	40	2.13	1.0	85
Total		40	2.13	1.0	85

The estimate of the number of respondents is based upon the current number of institutions certifying HHS-conducted or -supported subpart C human subjects research to OHRP. In 2025, OHRP received fifty-one certifications from thirty-eight institutions or organizations, and one hundred percent of the respondents submitted their certification information electronically. We project that, annually, forty institutions will submit certifications. Most respondents will submit the form twice annually; however, some respondents may submit the form 3 times annually. Consistent with 5 CFR 1320.5(a)(1)(iv)(5), therefore, we believe this estimate represents the

total annual reporting and recordkeeping burden that will result from the collection of information.

The burden is estimated to average one hour per Subpart C Certification Form and the total annual burden hours are projected to be eighty-five.

Catherine Howard,

Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.

[FR Doc. 2026–18950 Filed 9–15–26; 8:45 am]

BILLING CODE 4150–36–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Opportunity To Co-Sponsor Events With the Office of Research Integrity

AGENCY: Office of Research Integrity, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The Office of Research Integrity (ORI) announces an ongoing opportunity for non-federal public and private sector entities to co-sponsor conferences, workshops, symposia, meetings, roundtables, or other similar events (collectively, ''Events'') with ORI. ORI co-sponsors a limited number of Events with non-federal entities each year. Potential co-sponsors must have demonstrated interest and experience in the responsible conduct of research or handling allegations of research misconduct and must be willing to substantively contribute to the co-sponsored Event. This notice supersedes ORI's October 21, 2022, co-sponsorship opportunity notice at 87 FR 64067.

DATES: Expressions of interest for co-sponsoring an Event with ORI may be submitted starting October 1, 2026, and will be reviewed on an ongoing basis.

ADDRESSES: Expressions of interest for co-sponsoring an Event with ORI should be sent by email to *ORIComms@HHS.GOV* with ''Co-sponsoring an Event with ORI'' in the subject field.

FOR FURTHER INFORMATION CONTACT:

Chenelle Johnson, Program Analyst, U.S. Department of Health and Human Services (HHS) at (240) 268–0775

Mia Brown, Public Health Analyst, U.S. Department of Health and Human Services (HHS) at (240) 453–8265, *ORIComms@HHS.GOV* .

SUPPLEMENTARY INFORMATION:

Background: ORI oversees and directs U.S. Public Health Service (PHS) research integrity activities on behalf of the Secretary of Health and Human Services, except for the regulatory research integrity activities of the Food and Drug Administration. ORI is a program office within the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health in the Office of the Secretary.

Core to ORI's mission are education activities for PHS-funded research institutions to teach the responsible conduct of research, promote research integrity, prevent research misconduct, and enable such institutions to respond effectively to allegations of research misconduct. (65 FR 30600, 30601 [May 12, 2000]). Co-sponsored Events contribute to this mission by providing education, training, and/or the opportunity to discuss topics such as handling allegations of research misconduct and fostering research integrity, the responsible conduct of research, and gold standard research practices. Gold standard research exemplifies the highest levels of scientific rigor, transparency, reproducibility, and adherence to ethical standards. Co-sponsored Events typically accept between 20 and 150 attendees and convene for one to three days.

Co-sponsors will work with ORI staff to jointly develop an Event. Both ORI and co-sponsors must contribute substantively to the development of the Event. Co-sponsors may charge registration fees but only at levels necessary to recover Event-related expenses. Co-sponsors are also solely responsible for collecting and handling any registration fees.

Eligibility for Co-Sponsorship: Potential co-sponsors must:

- Have demonstrated interest and experience in fostering the responsible conduct of research or handling allegations of research misconduct.
- Substantively contribute to the content of the co-sponsored Event beyond funding, logistical services, or other material support.

Expression of Interest in Co-Sponsorship: An entity may submit an expression of interest individually or jointly with other entities, describing their relative contributions. Please note that ORI may hold exploratory discussions with potential co-sponsors after initial review of submissions. Entities interested in co-sponsoring an Event with ORI should submit a one- to two-page, single-spaced document in at least 11-point font that includes the following:

1. Contact information for the entity's representative(s), including full name, role, email address, and phone number.

2. A brief summary (one to two paragraphs) detailing why ORI should select the entity, including demonstrated interest and experience in the responsible conduct of research or handling allegations of research misconduct.

3. A bullet outline addressing the eight topics listed below (roughly one paragraph each):

a. The entity's demonstration of leadership and management of matters involving research integrity.

b. The entity's prior experience and current readiness to undertake the responsibilities of co-sponsoring an Event with ORI.

c. The type of Event(s) that the entity is interested in co-sponsoring with ORI.

d. The entity must be willing to substantively contribute to the co-sponsored Event.

e. Facilities available for the Event(s), including the distance from the facilities to a major airport.

f. Any current constraints with respect to dates or facilities, and a suggested time frame of dates (at minimum, month(s) and year for the Event).

g. Whether the entity has co-sponsored an Event with ORI in the past 36 months.

h. Whether the entity has any active research misconduct proceedings (regardless of status) of which ORI is unaware.

Evaluation Criteria: After engaging in exploratory discussions with potential co-sponsors who respond to this notice, HHS will apply the following five considerations, as appropriate and relevant, to select the co-sponsor(s):

1. Qualifications and capability to fulfill co-sponsorship responsibilities.

2. Suitability of the location of the proposed Event in terms of the overall geographical distribution of recent or planned ORI Events.

3. Potential for the Event to engage an adequate number of attendees.

4. Availability and description of facilities needed to support the Event.

5. Availability of administrative support for the logistics of hosting the Event.

The duties of the co-sponsor will be outlined in a co-sponsorship agreement with ORI that will set forth details of the co-sponsored Event, including the requirement that any fees collected by the co-sponsor shall be limited to the amount necessary to cover the co-sponsor's Event-related expenses. A co-sponsorship agreement does not represent an endorsement by ORI of an individual co-sponsor's policies, positions, or activities.

Loc Nguyen-Khoa,

Deputy Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2026–18987 Filed 9–15–26; 8:45 am]

BILLING CODE P